225 related articles for article (PubMed ID: 27633093)
21. Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells.
Amri J; Molaee N; Karami H
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3361-3367. PubMed ID: 31759360
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1.
Mao M; Wu Z; Chen J
Biochem Biophys Res Commun; 2016 Sep; 478(2):649-55. PubMed ID: 27495872
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
24. miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.
Gan CZ; Li G; Luo QS; Li HM
IUBMB Life; 2017 Nov; 69(11):841-849. PubMed ID: 28940895
[TBL] [Abstract][Full Text] [Related]
25. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
26. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.
Xu X; Jin S; Ma Y; Fan Z; Yan Z; Li W; Song Q; You W; Lyu Z; Song Y; Shi P; Liu Y; Han X; Li L; Li Y; Liu Y; Ye Q
J Mol Med (Berl); 2017 Aug; 95(8):861-871. PubMed ID: 28487996
[TBL] [Abstract][Full Text] [Related]
27. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-125a-5p modulates radioresistance in LTEP-a2 non-small cell lung cancer cells by targeting SIRT7.
Sun C; Zeng X; Guo H; Wang T; Wei L; Zhang Y; Zhao J; Ma X; Zhang N
Cancer Biomark; 2020; 27(1):39-49. PubMed ID: 31683458
[TBL] [Abstract][Full Text] [Related]
29. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
30. Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
Bisagni A; Pagano M; Maramotti S; Zanelli F; Bonacini M; Tagliavini E; Braglia L; Paci M; Mozzarelli A; Croci S
PLoS One; 2018; 13(4):e0196350. PubMed ID: 29689091
[TBL] [Abstract][Full Text] [Related]
31. Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer.
Shao Y; Shen YQ; Li YL; Liang C; Zhang BJ; Lu SD; He YY; Wang P; Sun QL; Jin YX; Ma ZL
Oncotarget; 2016 Jun; 7(23):34011-21. PubMed ID: 27049724
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
Flamini V; Jiang WG; Cui Y
Anticancer Res; 2017 Aug; 37(8):4319-4327. PubMed ID: 28739724
[TBL] [Abstract][Full Text] [Related]
33. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
[TBL] [Abstract][Full Text] [Related]
34. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells.
Ma Z; Qiu X; Wang D; Li Y; Zhang B; Yuan T; Wei J; Zhao B; Zhao X; Lou J; Jin Y; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2015 Aug; 47(8):630-8. PubMed ID: 26124189
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer.
He D; Wang J; Zhang C; Shan B; Deng X; Li B; Zhou Y; Chen W; Hong J; Gao Y; Chen Z; Duan C
Mol Cancer; 2015 Apr; 14():73. PubMed ID: 25889562
[TBL] [Abstract][Full Text] [Related]
36. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
37. LncRNA DGCR5 contributes to CSC-like properties via modulating miR-330-5p/CD44 in NSCLC.
Wang R; Dong HX; Zeng J; Pan J; Jin XY
J Cell Physiol; 2018 Sep; 233(9):7447-7456. PubMed ID: 29663359
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
39. miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.
Su W; Mo Y; Wu F; Guo K; Li J; Luo Y; Ye H; Guo H; Li D; Yang Z
Biomed Pharmacother; 2016 Dec; 84():123-129. PubMed ID: 27643554
[TBL] [Abstract][Full Text] [Related]
40. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
